Iomed Plans NDA Filing For Iontophoretic Dexamethasone - IPO Prospectus
Executive Summary
Iomed will seek FDA approval under the NDA process for use of dexamethasone with its Phoresor iontophoresis drug delivery device for treatment of acute inflammatory conditions, the Salt Lake City company said in its initial public offering prospectus.